cholecalciferol and Hot-Flashes

Topics: Bone Density Conservation Agents; Cardiovascular Diseases; Cholecalciferol; Diphosphonates; Gastrointestinal Diseases; Hot Flashes; Humans; Hypercalcemia; Jaw Diseases; Macular Edema; Necrosis; Osteoporosis; Raloxifene Hydrochloride; Venous Thrombosis

The aim of this study was to assess the effects of a phyto complex on menopausal symptoms.. A total of 151 women aged 42-67 years were enrolled. They were in spontaneous or surgical menopause by at least 12 months, reporting symptoms referable to the climacteric syndrome. Two validated and standardized tests were given to the whole sample at the entrance of the study (T0) and after 6 months of treatment (T6): the Greene Climacteric Scale (GCS) and the Beck Depression Inventory (BDI). Interim evaluations were carried out at 1-3 months (T1 and T3) on five symptoms selected from the GCS. The phyto complex was given to each enrolled woman, from the T0 to T6 time-points, for a total of 180 days.. At the T0 time-point, the average scores were: GCS, 28.98 (standard deviation [SD] ± 10.71); BDI, 14.48 (SD ± 6.5). At the T1 time-point, five parameters of the GCS were assessed with a reduction of 36.25% in symptoms (5.69, SD ± 3.53). At the T6 time-point the assessment was completed: average GCS results were 11.54 (SD ± 8.01) with a 60.17% improvement; and average BDI results were 6.11 (SD ± 4.6) with a 58.91% improvement in the depressive symptoms.. The phyto complex under consideration is an effective tool to counter, in a quick and long-lasting manner, the most common and nagging symptoms of the climacteric syndrome, such as hot flushes, insomnia and depression.

Topics: Adult; Aged; Anxiety; Cholecalciferol; Depression; Diagnostic and Statistical Manual of Mental Disorders; Dietary Supplements; Drug Combinations; Female; Genistein; Gluconates; Hot Flashes; Humans; Middle Aged; Phytoestrogens; Plant Extracts; Plant Preparations; Postmenopause; Psychiatric Status Rating Scales; Severity of Illness Index; Sicily; Sleep Initiation and Maintenance Disorders; Vitamin E

A combination of calcium, vitamin D3, lycopene , astaxantin and Citrus bioflavoid (MF Afragil®) was administered for a period of 8 weeks to 65 women to determine its effects in reducing signs/symptoms of climacteric status.. Two groups of women were compared in a registry study (33 treated with MF Afragil® and 32 with no treatment). The climacteric condition was determined by using the 34-symptom questionnaire MSSQ, which was filled out at inclusion in the trial and after 8 weeks of treatment. The MSSQ signs/symptoms scores (Common Symptoms, Changes and Pains) of the two groups were comparable at inclusion, whereas after 8 weeks a significant reduction of many variables was found in the group treated with MF Afragil® and in the control group.. Following the treatment with MF Afragil®, the total MSSQ score was reduced by more than 45%. There was a significant reduction in hot flashes, CNS symptoms (depression, anxiety and panic disorders), incontinence and joint pain, which are among the most frequent symptoms of climacteric status. Otsteoporosis was not analyzed due to the short period of treatment.. MF Afragil® was found to be efficient in reducing climacteric symptoms following a short-term administration. More prolonged treatment and more cases are under analysis to also determine its effect on osteroporosis.

Topics: Aged; Body Mass Index; Calcium; Carotenoids; Cholecalciferol; Citrus; Drug Combinations; Female; Flavonoids; Free Radicals; Hot Flashes; Humans; Lycopene; Menopause; Middle Aged; Pilot Projects; Treatment Outcome; Xanthophylls

To evaluate the effect of soy isoflavones and inulin (SII) on hot flushes (HF) and quality of life in a clinical setting, the authors conducted an observational study.. The authors performed an observational, prospective, multicentric study on women in peri-/post-menopause treated or untreated with a product present on the Italian market, consisting in a mixture of calcium (500 mg), vitamin D3 (300 IU), inulin (3 g) and soy isoflavones (40 mg).. A total of 135 patients, 75 (55.6%) in the SII group and 60 (44.4%) in the untreated group entered the study. After three months, the mean number of HF declined of 2.8 (SD 3.7) in the SII group and 0.0 in the untreated one. The corresponding values after six months were -3.7 (SD 2.7) in the SII group and -0.9 (SD 5.3) in the control group (p = 0.02).. This observational trial suggests a possible beneficial effect of a dietary soy supplement containing 40 mg of isoflavone/day plus inulin in the management of menopausal symptoms such as hot flashes.

Topics: Calcium; Cholecalciferol; Dietary Supplements; Drug Therapy, Combination; Female; Glycine max; Hot Flashes; Humans; Inulin; Isoflavones; Menopause; Middle Aged; Prospective Studies; Quality of Life; Treatment Outcome